Trulieve Cannabis
- Market cap
- 2.08B
- P/E (TTM)i
- -4.36
- P/Bi
- 2.71
- EPSi
- -0.61
- Div yieldi
- 0.00%
- 52W posi
- 71%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Trulieve Cannabis (TRLV) | 2.08B | -4.36 | 2.71 | 0.00% |
| Takeda Pharmaceutical (TAK) | 58.68B | -55.67 | 1.23 | 3.26% |
| Teva Pharmaceutical Industries (TEVA) | 45.70B | 65.30 | 5.89 | 0.00% |
| Haleon (HLN) | 39.67B | 18.87 | 1.83 | 2.11% |
| Zoetis (ZTS) | 29.57B | 11.67 | 9.39 | 2.88% |
| United Therapeutics (UTHR) | 23.38B | 19.53 | 3.65 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 16.8% below Morningstar's fair value estimate.
Fair value
Trulieve Cannabis Corp earns a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 15% discount to our quantitative fair value estimate of $12.59 per share; however, caution is warranted due to this estimate's high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
The company's balance sheet strengthens our quantitative valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its current ratio of 5.9, which sits in the top 10% compared with peers globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.
Conversely, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 1.1%, a core component of profitability, falls in the bottom 40% globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-08 08:19:27 · For reference only, not investment advice and not tailored to your situation.